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Chris I. Shaffrey,6 Brian K. Kwon,7 Jens Chapman,8 Albert Yee,1 Allyson Tighe,1 and Lisa McKerracher4
Abstract
Multiple lines of evidence have validated the Rho pathway as important in controlling the neuronal response to
growth inhibitory proteins after central nervous system (CNS) injury. A drug called BA-210 (trademarked as
Cethrin) blocks activation of Rho and has shown promise in pre-clinical animal studies in being used to treat
spinal cord injury (SCI). This is a report of a Phase I/IIa clinical study designed to test the safety and tolerability
of the drug, and the neurological status of patients following the administration of a single dose of BA-210
applied during surgery following acute SCI. Patients with thoracic (T2-T12) or cervical (C4-T1) SCI were se-
quentially recruited for this dose-ranging (0.3mg to 9mg Cethrin), multi-center study of 48 patients with
complete American Spinal Injury Association assessment (ASIA) A. Vital signs; clinical laboratory tests; com-
puted tomography (CT) scans of the spine, head, and abdomen; magnetic resonance imaging (MRI) of the spine,
and ASIA assessment were performed in the pre-study period and in follow-up periods out to 1 year after
treatment. The treatment-emergent adverse events that were reported were typical for a population of acute SCI
patients, and no serious adverse events were attributed to the drug. The pharmacokinetic analysis showed low
levels of systemic exposure to the drug, and there was high inter-patient variability. Changes in ASIA motor
scores from baseline were low across all dose groups in thoracic patients (1.8 – 5.1) and larger in cervical patients
(18.6 – 19.3). The largest change in motor score was observed in the cervical patients treated with 3mg of Cethrin
in whom a 27.3 – 13.3 point improvement in ASIA motor score at 12 months was observed. Approximately 6% of
thoracic patients converted from ASIA A to ASIA C or D compared to 31% of cervical patients and 66% for the 3-
mg cervical cohort. Although the patient numbers are small, the observed motor recovery in this open-label trial
suggests that BA-210 may increase neurological recovery after complete SCI. Further clinical trials with Cethrin
in SCI patients are planned, to establish evidence of efficacy.
Key words: ASIA; Cethrin; clinical trial; motor recovery; Rho
Introduction
Primary cell loss and the absence of meaningful regen-eration after spinal cord injury (SCI) are major impedi-
ments to recovery. Ground-breaking studies more than three
decades ago demonstrated the intrinsic capacity of injured
neurons to regenerate (David and Aguayo, 1985; Richardson
et al., 1980), and despite awareness of the existence of growth
inhibition in the central nervous system (CNS) since the late
1980s (Schwab et al., 1993), the specifics of the complex in-
teractions that control axon regeneration are still under in-
tense investigation. Molecules associated with myelin debris,
as well as extracellular matrix molecules in the glial scar,
among others have been shown to cause growth cone collapse
in injured axons and to inhibit regeneration (Fitch and Silver,
2008; Li et al., 2004; Rowland et al., 2008). Myelin-associated
inhibitors signal through the Nogo receptor (NgR), which is
present on the nascent growth cone of a regenerating axon
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(Sandvig et al., 2004), and mediate growth cone collapse by
activating Rho (Dubreuil et al., 2003). Recent studies have
shown that NgR does not have an intracellular domain, and
must therefore recruit a receptor complex to propagate signals
(Mi et al., 2004). The p75NTR portion of the receptor complex
(Fig. 1) signals directly to Rho, converting Rho to an activated
state (Yamashita et al., 2002, 2005). Chondroitin sulphate
proteoglycans, inhibitory extracellular matrix molecules that
are associated with the glial scar, have also been shown to act
through the Rho signalling pathway to inhibit axon regener-
ation (Dergham et al., 2002, Monnier et al., 2003). Rho
GTPases are key intracellular enzymes that regulate cyto-
skeletal mechanics and cellular motility. Rho activation and
the downstreamactivation of Rho-associated kinase leads to an
imbalance in the phosphorylation state of myosin light chain
and, consequently, a collapse of the growth cone scaffold and
axon growth arrest. The convergence of several inhibitory
signalling pathways on the Rho pathwaymakes it an attractive
target for regenerative therapies. Previous studies have shown
that the inactivation of RhoA (a member of the Rho family of
proteins) using C3 transferase, or the inhibition of Rho kinase
with the pharmacological inhibitor Y-27632, can promote axon
outgrowth on inhibitory substrates in vitro and in vivo (Borisoff
et al., 2003; Dergham et al., 2002, Lord-Fontaine et al., 2008). It
has also been shown that the inactivation of RhoA with C3
transferase protects neurons from cell death after ischemia or
trauma (Bertrand et al., 2007, Dubreuil et al., 2003).
C3 transferase, an enzyme from Clostridium botulinum,
blocks the Rho signalling pathway by locking RhoA in the
inactive state. C3 transferase has been shown to reverse the
effect of extracellular inhibitory substrates on neurons in
culture and to enable the outgrowth of neurites ( Jin and
Strittmatter, 1997; Lehmann et al., 1999). Local application of
C3 transferase to the injury site in a mouse hemi-section
model of SCI resulted in long-distance regeneration of cortico-
spinal neurons, increased expression of growth-associated
protein-43 in the motor cortex, and improved functional re-
covery as assessed by locomotor scores and limb coordination
(Dergham et al., 2002; Lord-Fontaine et al., 2008) . However,
cell penetration by the wild-type C3 transferase is very low,
limiting its clinical development as a therapeutic agent. BA-
210 is a recombinant engineered variant of C3 transferase that
can readily cross the dura of the spinal cord as well as the cell
membrane via a receptor-independent mechanism, and is
being developed under the drug Cethrin (Lord-Fontaine et al.,
2008). Epidural administration of Cethrin to the site of injury
in a fibrin sealant carrier inactivates RhoA, reduces the extent
of the lesion, and improves functional recovery in rodent
models of SCI. Moreover, Cethrin penetrates to the ventral
spinal cord when applied to the dorsal spinal cord in animal
models (Lord-Fontaine et al., 2008).
This clinical trial was undertaken to assess the safety and
tolerability of the drug, and the neurological status of patients
treated with escalating doses Cethrin (ranging from 0.3mg to
9mg). We chose a noninvasive, fibrin-mediated delivery
method, as its use has been supported by experimental
studies in rodents (Guest et al., 1997; Kassam et al., 2004) and
it is used routinely by spinal surgeons (Nakamura et al., 2005).
We hypothesized that a single dose of Cethrin, applied to the
dura mater of the injured spinal cord, would be well tolerated
and clinically feasible to administer, and would improve the
neurological outcome of patients with cervical or thoracic SCI
as measured by the American Spinal Injury Association
(ASIA) assessment.
Methods
Subjects and study design
The planned enrollment was 35–60 patients, and a total of
48 patients were enrolled in the trial, 32 with thoracic injury
FIG. 1. Schematic of Cethrin application and mechanism of action. Cethrin is applied to the injured spinal cord extradurally
and exerts its effects by blocking the activation of Rho, thereby encouraging neurite outgrowth.
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(T2-T12), and 16 with cervical injury (C4-T1) aged 16–70 years
inclusive. All patients had acute, complete (ASIA Impairment
Scale Grade A) SCI and were scheduled to undergo spinal
decompression surgery or other interventional spinal surgery
(e.g., fixation) within 7 days of injury. The study was ap-
proved as an Investigation of a New Drug by the Food and
Drug Administration (USA) and by a Clinical Trial Applica-
tion to Health Canada (Canada), and monitored by an inde-
pendent Data-Safety Monitoring Board (DSMB). Age-eligible
participants were recruited from February 3, 2005 to No-
vember 15, 2007. Patients were selected for the study from
nine clinical sites in the United States and Canada.
Five different doses of Cethrin were studied; 0.3mg, 1mg,
3mg, 6mg, and 9mg. Dosing was first tested in thoracic pa-
tients because this cohort would be least affected if there was
worsening in the level of neurological injury, as re-
commended by the International Campaign for Cures for
spinal cord injury Paralysis (ICCP) guidelines (Fawcett et al.,
2007). After the DMSB determined that the drugwas safe in at
least five thoracic patients (Figure 2), cervical patients were
enrolled at the same dose. The DMSB also reviewed the safety
data before approval of dose escalation. Each patient received
a single application of Cethrin at the time of surgery. The
route of administrationwas a local application of Cethrin onto
the anterior or posterior dural surface area overlying the in-
jured spinal cord, upon completion of decompression and
instrumentation, for patients undergoing spinal decompres-
sion or fixation surgery by a neurosurgeon or orthopaedic
surgeon. The protocol directed a solitary application of Ce-
thrin for each patient.
Patients were assessed for suitability for entry into the trial
during the pre-study period: vital signs, physical examina-
tion, clinical laboratory tests, and ASIA assessment were
performed. All centers in the study adhered to the acute SCI
management guidelines published by a consensus panel in
2002 (Hadley et al., 2002). These guidelines included avoid-
ance of hypotension with induced hypertension (mean> 85
mm Hg), and early intervention with surgical decompression
and reconstruction (within 72 h when medically feasible). The
mean time for drug administration was at 52 h as described in
detail in the Results section. Baseline computed tomography
(CT) scans of the spine, head, and abdomen were completed
during the pre-study period. Magnetic resonance imaging
(MRI) of the spine in the area of presenting injury and of the
head were preformed during the pre-study period, 72–96 h
following surgery, and at week 6. Results of any additional
scans performed at the investigator’s discretion as part of the
standard of care were recorded.
Inclusion/exclusion criteria
Potential participants were excluded if any of the following
conditions were present: (1) use of any experimental drug,
or participation in any clinical trial, within 30 days prior to
Cervical Patient Group
Enrol 5-8 patients at 0.3 mg; treat; collect safety data 
through Week 6 for 2 patients and through Week 3 for 3 
additional patients; Data Safety Monitoring Board 
(DSMB) review and approval to proceed. (n=5)
Solid : Safety results acceptable
* Data were reviewed for the first 6 mg thoracic patients and it was deemed safe to dose the 6 
mg cervical patients and the 9 mg thoracic patients.
(n= #) Actual number of patients assessed
Enrol 2-4 patients at 0.3 mg; treat; 
collect safety data through Week 3
for 2 patients; DSMB review and 
approval to proceed. (n=3)
Enrol 2-4 patients at 1 mg; treat; 
collect safety data through Week 3
for 2 patients; DSMB review and 
approval to proceed. (n=4)
Enrol 2-4 patients at 3 mg; treat; 
collect safety data through Week 3
for 2 patients; DSMB review and 
approval to proceed. (n=3)
Enrol 5-8 patients at 1 mg; treat; collect safety data 
through Week 6 for 2 patients and through Week 3 for 3 
additional patients; DSMB review and approval to 
proceed. (n=6)
Enrol 5-8 patients at 3 mg; treat; collect safety data 
through Week 6 for 2 patients and through Week 3 for 3 
additional patients; DSMB review and approval to 
proceed. (n=7)
Enrol 5-8 patients at 6 mg; treat; collect safety data 
through Week 6 for 2 patients and through Week 3 for 3 
additional patients; DSMB review and approval to 
proceed*. (n=6)
Enrol 2-4 patients at 6 mg; treat; 
collect safety data through Week 3; 
DSMB review and approval to 
proceed. (n=4)
Thoracic Patient Group
Enrol 5-8 patients at 9 mg; treat; collect safety data 
through Week 6 for 2 patients and through Week 3 for 3 
additional patients; DSMB review and approval to 
proceed*. (n=8)
Enrol 2-4 patients at 9 mg; treat; 
collect safety data through Week 3; 
DSMB review and approval to 
proceed. (n=2)
FIG. 2. Study design for patient recruitment.
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surgery; (2) history of adverse reaction to fibrin sealant; (3)
history of hypersensitivity to bovine products; (4) any medical
condition that might interfere with the ASIA assessments;
(5) clinically significant neurological, cardiac, respiratory, he-
patic, or renal disease or malignancy; (6) hemophilia or other
bleeding abnormality as defined by a platelet level< 100· 109/
L, activated partial thromboplastin time or international nor-
malized ratio higher than the upper limit of normal, and/or a
baseline hematocrit < 0.25; (7) gunshot wound as the present-
ing injury, or any evidence of transecting injury to the spinal
cord (e.g., by stab wound); (8) cognitive impairment that could
preclude accurate neurological assessments (e.g. traumatic
brain injury with GlasgowComa Scale of £ 14); (9) ankylosing
spondylitis; (10) diabetes mellitus requiring insulin therapy;
(11) known immunodeficiency, including AIDS, or use of
immunosuppressive or cancer chemotherapeutic drugs; (12)
pregnancy or breastfeeding during the study; (13) any condi-
tion or situation likely to cause the patient to be unable or
unwilling to participate in the study or follow-up; (14) any
condition likely to result in the patient’s death within the next 6
months; (15) any other condition that, in the opinion of the
investigator, would preclude the patient’s participation in the
study; (16) previous participation in this study; (17) use of in-
travenous heparin in the previous 48h or thrombolytics and/
or aspirin containing products in the previous 10 days; or (18)
non-traumatic causes of spinal cord injury (e.g. transverse
myelitis, acute disc herniation). Dural tear was not a contrain-
dication to enrolment. Of the recuited patients 31% were re-
ported to have dural tears, and in 69 % the dura was intact.
Dose and drug delivery
The starting dose of 0.3mg chosen for study was based on
the ‘‘no observed adverse effect’’ level determined from pre-
clinical safety studies. A total of seven toxicology studies, two
non-Good Laboratory Practice (GLP) studies and five GLP
studies, were conducted in rats, dogs, and pigs to evaluate the
safety of Cethrin administered intravenously and subcuta-
neously, as well as Cethrin prepared with Tisseel adminis-
tered extradurally to the spinal cord. The five GLP toxicology
studies comprised four acute studies in rats and dogs and one
repeated-dose study in rats. In these GLP studies, more than
400 rats and 24 dogs were studied. The human equivalent safe
doses were calculated to be 3.5mg/kg based on body weight,
or 10mg based on relative spinal cord surface area. The
starting dose of 0.3mg in humans was predicted to be within
the effective dose range, based on contusion studies in rats,
and Rho inactivation patterns in injured rat spinal cord after
application of BA-210 (Lord-Fontaine et al., 2008).
For effective and simple delivery of Cethrin to the site of SCI,
BA-210 was combined with a fibrin sealant product at the
clinical site (Fig. 1). Fibrin sealants are provided as single-use
kits consisting of four components (five components in Cana-
da) packed in separate vials (Tisseel; Baxter, Deerfield, IL). The
1mL size was used in this study. The components of the kit are
fibrinogen and reconstitution buffer containing bovine aproti-
nin; thrombin (in Canada two thrombin vials are included and
500 IU/mL was used) with reconstitution buffer containing
calcium chloride. The fibrinogen and thrombin were recon-
stituted by mixing with their respective buffer solutions. BA-
210 was formulated in 5mM sodium citrate buffer pH 6.5 and
was supplied as 0.5mL in a 2mL vial at a concentration of
30mg/mL. The BA-210 solution was kept frozen at - 20C
until used. The final BA-210 doses were prepared within 1h
prior to surgery from the 30mg/mL solution and co-applied
with the thrombin and fibrinogen solutions by use of the Du-
ploject applicator (Baxter Healthcare Corporation, Deerfield,
IL). The applicator is a double-barreled syringe that separates
the fibrinogen and thrombin until the plunger is pushed,which
mixes the solutions simultaneously with delivery.
Outcome measures
The primary objective was to determine the safety and tol-
erability of escalating doses of BA-210. The primary safety pa-
rameter was unexpected worsening in neurological function at
week 6. The secondary objectives were to evaluate the phar-
macokinetic profile of BA-210, immunologic parameters fol-
lowing exposure to BA-210, and the neurological status of
patients as measured by the ASIA assessment (Steeves et al.,
2007). The motor score ASIA assessments were completed
within 12h prior to surgery and between 48 and 72h following
surgery, as well as at postoperative months 3, 6, and 12 as fol-
low-up. Safety was assessed by evaluating vital signs, clinical
laboratory and MRI results, as well as any adverse events. All
patients receivedMRI scans of the brain and spinal cord prior to
surgery, as well as 3 days and 6 weeks after BA-210 application,
to assess the safety of the treatment and to exclude the possibility
of exacerbation of the lesion by the experimental treatment.
Safety and adverse events. Adverse events were re-
corded as follows: reports spontaneously volunteered by the
patients; events recorded by the investigator; and investiga-
tor-elicited reports in response to open-ended questions. Pa-
tients with acute thoracic (T2-T12) SCI were treated before
patients with acute cervical (C4-T1) SCI and cervical patients
were only recruited into the study once there was cumulative
safety data for at least two patients from the same dose group
who had completed the week 6 assessments (Fig. 2).
The dose level of a patient was determined by the dose the
patient received, not necessarily the dose to which he or she
was assigned. Three deviations were reported for dose ad-
ministration: (1) Patient 01-1-02 was assigned to receive
0.3mg of BA-210. Analysis of the dosing solution revealed
that the patient had received a 3-mg dose of BA-210. (2) Pa-
tient 04-1-01 was assigned to receive 1mg of BA-210. The
patient had received a 2-mg dose of BA-101. (3) For Patient 08-
1-02, the time that the dose was administered was not re-
corded; therefore, nominal times of sample collections were
used to compute parameters.
All patients who were enrolled and received one dose of
study medication were included in the summaries and ana-
lyses for safety, including any patient who withdrew early
from the study. A DSMB periodically reviewed safety data
from the study and made recommendations to stop/continue
enrollment of patients at a particular dose level or stop/con-
tinue the study. The primary population for efficacy analysis
was the intent-to-treat population that included all patients
who were enrolled and received any dose of study medica-
tion. Treatment-emergent adverse events were defined as all
adverse events occurring during the study period.
Pharmacokinetic analysis. Blood samples were obtained
for pharmacokinetic assessments before surgery and at 0.5, 1,
2, 6, 24, and 48 h following Cethrin application [during the
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intensive care unit (ICU) period]. Serum concentrations of BA-
210 were determined by enzyme-linked immunosorbent as-
say (ELISA).
Antibody levels. Blood sampleswere obtained tomeasure
antibody levels in serum before surgery and on day 10, week
6, and month 6 assessments. An ELISA assay was used to
measure serum concentrations of BA-210.
Neurological outcomes. Changes in ASIA grade from
baseline to each of the planned ASIA grade times for total
motor score were summarized using the mean and standard
deviation. The number and percentage of patients who shifted
from category A on the ASIA impairment scale to categories
B, C, D, or E were tabulated by patient group, dose level, and
time for observed data.
Results
We enrolled 48 patients with acute, complete thoracic, or
cervical SCI (ASIA grade A) and thoracic patients were trea-
ted and assessed at each dose before the recruitment of cer-
vical patients (Fig. 2). Patients received a single dose of
BA-210 in fibrin 7.83 to 146.1 h after the initial injury (mean
52.6 h). Thirty-five of the 48 patients enrolled completed the
trial: 23 with complete thoracic SCI, and 12 with complete
cervical SCI. Of the patients who did not complete the study,
six were lost to follow-up, three were lost during the company
transition, two died, one withdrew consent, and one refused
to return to complete visits. The patients in the cervical and
thoracic groups were well matched for demographics, age,
and gender (Table 1).
Adverse events
The primary objective of the trial was to measure the safety
and tolerability of Cethrin when administered in conjunction
with fibrin sealant to the dura mater of the spinal cord. Safety
was assessed by vital signs, physical examination, clinical
laboratory and MRI results, as well as adverse events. Neu-
rological function was assessed by the ASIA assessment. The
adverse event profile indicated that Cethrin is safe and tol-
erable in the dose range studied (0.3–9mg). The reported
treatment-emergent adverse events were typical for a popu-
lation of acute SCI patients, and there were no serious adverse
events that were attributed to Cethrin by the clinical investi-
gators and the DSMB. In particular, there were no allergic
reactions, cardiopulmonary complications, or hemorrhagic
adverse events attributable to the medication. Table 2 sum-
marizes the serious adverse events in both the thoracic and
cervical cohorts in this trial. Two subjects died while enrolled
in the trial: one from adult respiratory distress syndrome; one
in a delayed fashion from a cerebral glioblastoma that became
apparent after enrolment in the trial. These deaths were at-
tributed to causes related to the subjects’ initial SCI, other
injuries, or pre-existing conditions, and were within or below
the expected death rate for an acute SCI population (Furlan
et al., 2010 ; Geisler et al., 2001) and determined not to have a
causal relation to Cethrin. The overall mortality was 2/48
patients (4%).
The urinary tract infection rate (a subset of infections, Table 2)
was consistent at all dose levels for the thoracic cohort of patients
(mean 75%); however, in the cervical cohort of patients the uri-
nary tract infection rate was lower, (mean 50%), and none of the
patients in the 3-mg group had urinary tract infection.
Table 1. Summary of Demographic Characteristics
0.3mg 1mg 3mg 6mg 9mg
Thoracic SCI n = 5 n = 6 n = 7 n = 6 n = 8 Overall
Race
Black 1 0 0 0 1 6%
Caucasian 4 5 7 3 7 81%
Other - Hispanic 0 0 0 2 0 6%
Other - Native American 0 1 0 1 0 6%
Gender
Male 3 5 5 6 8 84%
Female 2 1 2 0 0 16%
Age (Years)
Mean 43.2 27.6 40.7 22.2 33.3 Mean = 33.9
SD 3.3 12.3 15.9 8.3 16.6 +/ - 14.3
0.3mg 1mg 3mg 6mg 9mg Overall
Cervical SCI n = 3 n = 4 n= 3 n = 4 n = 2 n = 16
Race
Black 1 1 1 0 0 19%
Caucasian 2 2 2 4 2 75%
Other - Asian 0 1 0 0 0 6%
Gender
Male 2 4 2 3 2 81%
Female 1 0 1 1 0 19%
Age (Years)
Mean 42.0 38.0 48.3 46.3 24.5 Mean = 41.1
SD 25.1 16.4 14 18 6.4 +/ - 17
Patient 01-1-02 received a 3-mg dose instead of the assigned 0.3-mg dose; patient included according to the actual dose.
Patient 04-1-01 received a 2-mg dose instead of the assigned 1-mg dose; patient included according to intended dose.
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Pharmacokinetics
A summary of pharmacokinetic parameters is shown in
Table 3. For all treatment groups, the peak concentration
(CMAX) and the area under the curve parameters exhibited
high inter-patient variability. There was almost a twofold
greater observed maximum concentration when the dose was
applied to the thoracic site compared to the cervical site of SCI
for the 3-mg and 6-mg doses. The highest serum concentration
of the drug was in patients treated with 9-mg of Cethrin. The
meanCmax value at the effective dose range (1–3mg) was 0.8 to
2.3 for the cervical and thoracic patients, respectively. This
value is below the mean Cmax value (3.5 ng/mL) associated
with a dose of 0.01mg in rats in the extradural toxicity study,
which was considered a ‘‘no observed adverse effect’’ level. In
addition, the mean Cmax and AUC values for all of the patients
in this study were below the Cmax and AUC values for the low
doses tested in the intravenous toxicity studies in rats anddogs.
In cervical patients, only those treated with doses of ‡ 3mg
had levels of the drug that were above the limit of detection of
100 pg/mL. At all doses except the 9-mg dose, the plasma
levels were higher in the thoracic SCI patients than in the
cervical patients. At the very lowest doses, very few patients
hadmeasureable concentrations of Cethrin. All of the samples
Table 2. Patients with Treatment Emergent Adverse Events by System Organ class
0.3mg 1mg 3mg 6mg 9mg Overall
Thoracic Cohort n = 5 n= 6 n = 7 n= 6 n = 8 Percent
Blood lymphatic system disorders 4 0 1 4 2 34%
Cardiac disorders 0 0 1 0 0 3%
Ear and labyrinth disorders 0 0 1 1 0 6%
Endocrine disorders 1 0 0 0 0 3%
Eye disorders 1 0 0 0 1 6%
Gastrointestinal disorders 4 5 5 3 4 66%
General disorders 5 4 6 3 2 63%
Immune system disorders 0 1 0 0 0 3%
Infections 5 5 6 5 5 81%
Injury and procedural complications 1 1 1 2 4 28%
Investigations 3 2 4 0 3 37%
Metabolism and nutritional disorders 2 1 4 1 2 31%
Musculoskeletal and connective tissue disorders 1 3 5 5 4 56%
Neoplasms 0 0 1 0 0 3%
Nervous system disorders 1 2 5 2 4 44%
Psychiatric disorders 4 4 6 4 3 66%
Renal and urinary disorders 2 1 1 0 1 16%
Reproductive system disorders 0 1 1 1 1 13%
Respiratory, thoracic and mediastinal disorders 3 2 4 1 2 38%
Skin and subcutaneous tissue disorders 3 3 3 4 7 63%
Surgical and medical procedures 0 0 0 0 0 0%
Vascular disorders 1 1 3 1 4 31%
Cervical Cohort N = 3 N= 4 N = 3 N= 4 N = 2 Percent
Blood and lymphatic system disorders 1 3 1 1 1 44%
Cardiac disorders 0 0 0 1 1 13%
Ear and labyrinth disorders 0 0 0 1 1 13%
Endocrine disorders 0 0 0 0 0 0%
Eye disorders 0 0 0 0 1 6%
Gastrointestinal disorders 3 2 1 4 2 75%
General disorders 3 2 1 4 2 75%
Immune system disorders 0 0 0 0 0 0%
Infections 3 4 1 4 2 88%
Injury and procedural complications 1 1 2 1 1 38%
Investigations 1 2 2 1 2 50%
Metabolism and nutritional disorders 1 1 1 1 2 38%
Musculoskeletal and connective tissue disorders 1 2 1 2 2 50%
Neoplasms 0 0 0 0 0 0%
Nervous system disorders 2 0 0 1 2 31%
Psychiatric disorders 3 3 2 3 2 81%
Renal and urinary disorders 0 0 0 1 0 6%
Reproductive system disorders 0 0 0 0 0 0%
Respiratory, thoracic and mediastinal disorders 3 3 1 4 2 81%
Skin and subcutaneous tissue disorders 2 0 1 3 2 50%
Surgical and medical procedures 0 0 0 0 1 6%
Vascular disorders 1 1 3 3 2 63%
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from patients with cervical SCI who received the 0.3-mg and
1-mg dose were below the limit of quantitation
Antibody testing
Cethrin is a protein drug and patients were tested for the
development of antibodies against the drug at day 10, week 3,
week 6, month 3, and month 6. By month 6, 50% of patients in
the thoracic group and 38% of patients in the cervical group
had developed detectable levels of anti-Cethrin antibody.
Neurological outcomes
Recovery ofmotor function in patients with complete SCI is
fairly limited, and therefore, neurological motor scores (ASIA
Impairment Scale motor scores) are often utilized in Phase I
and Phase II SCI trials to determine if an experimental inter-
vention has potential beneficial effects (Fawcett et al., 2007).
We observed a large preliminary effect in ASIA motor scores
in subjects with complete cervical SCI. The largest mean
changes in ASIA motor scores were seen in the cervical pa-
tients treatedwith 1mg and 3mg of Cethrin (Fig. 3). The ICCP
Clinical Guidelines Panel reports that a cervical ASIA Grade
A-injured patient is likely to spontaneously improve by ap-
proximately 10 motor points during the first year after SCI,
whereas we observed average improvements of 21.3 and 27.3
points in the 1-mg and 3-mg groups, respectively, at 12
months (Fig. 4). There was little, if any, effect in the thoracic
injury cohort, and the average change for baseline for all doses
in thoracic patients was (1.8 – 5.1) compared to an overall
average change of (18.6 – 19.3) for all cervical patients. Ana-
logous to the findings with motor scores, patients in the cer-
vical cohort showed improvement in sensory scores. Very
little, if any, improvements in sensory scores were observed in
the thoracic cohort, at any dose (data not shown).
Motor function data were also analyzed in terms of conver-
sion on the ASIA Impairment Scale. All patients recruited into
the study had a severe SCI, andwere classified as ASIAA. At 12
months after treatment 31% (5/16) of subjects with cervical SCI
and 6.3% (2/32) of subjects with thoracic SCI improved over the
time period to at least ASIA C. In the 3-mg cervical group, 66%
improved toASIACor better. One cervical SCI subject in each of
the 1-mg and 3-mg dose cohorts improved to ASIA Grade D
(Fig. 5), and one subject with a thoracic injury in the 6-mg dose
cohort improved to ASIA Grade D.
Discussion
In this multicenter trial involving nine sites, we report for
the first time a safe and effective method of delivering a
biological drug to the injured spinal cord that does not confer
the risks associated with direct injection in the spinal cord or
intrathecal administration, techniques that have been used in
other SCI clinical trials (Blight and Tuszynski, 2006). The
primary outcome measure for this trial was the safety and
tolerability of increasing doses of Cethrin. Adverse events for
both the thoracic and cervical cohorts were most frequently
recorded for the following system organ classes: gastrointes-
tinal disorders; general disorders; infections; and psychiatric
disorders. None of the serious adverse events were assessed
as drug related. The incidence of events was consistent across
dose levels and was attributed to the original injury or asso-
ciated with medication administered to alleviate conditions
Table 3. Summary of Pharmacokinetic Parameters
Group Dose (mg) Number Cmax (ng/mL) AUC(0-t) (ng(h/mL) Tmax (h) T1/2* (h)
Thoracic 0.3 2 0.2 – 0.1 0.5 – 0.5 3.5 – 3.5 NA
1.0 4 0.7 – 0.8 7.8 – 9.4 3.6 – 2.8 12.6
3.0 6 2.3 – 1.9 47– 20 4.5 – 2.3 14.6 – 5.5
6.0 5 3.4 – 4.4 54– 56 3.3 – 2.5 13.3 – 5.8
9.0 7 6.2 – 5.4 51– 49 2.1 – 1.7 25.9 – 25.7
Cervical 0.3 0 NA NA NA NA
1.0 0 NA NA NA NA
3.0 3 0.8 – 0.1 6.8 – 9.4 10.6 – 11.7 NA
6.0 4 2.0 – 1.8 53– 71 2.0 – 2.4 14.2 – 8.2
9.0 2 12– 2.3 271– 243 3.5 – 3.5 16.6 – 2.7
NA, not available.
Number of patients for the T1/2 values were n = 1, n = 6, n = 3, n = 3 for 1-mg, 3-mg, 6-mg, and 9-mg values, respectively, and were n = 3 for
the 3-mg cervical group.
FIG. 3. Change in motor score over time for all treatment.
The cervial cohort of patients and thorcic cohort of patients
were followed for 52 weeks. The mean change in ASIA
motor scores is shown for each dose group at each time
point. Ten key muscle groups, five in the arm and five in the
leg, were tested bilaterally, and given a score of 0–5 each,
resulting in a possible total score of 100.
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that stemmed from the original injury, such as constipation,
nausea, urinary tract infection, anxiety, depression, and in-
somnia. It should be noted that adverse events are expected to
occur in patients following SCI.
MRI was used during the pre-screening period, at 72–96 h
following surgery, and at week 6 as a qualitative measure to
detect the location of the injury, degree of severity, and po-
tential complications. Whereas MRI was an essential diag-
nostic tool in this study, it does not as yet have the resolution
to be used to follow recovery or predict outcome.
Two patients died during this study, which is in the range
or lower than the expected number of deaths in an acute SCI
population (Furlan et al., 2010; Giester et al., 2001) . One of
these patients, a 67- year-old white man with a thoracic SCI,
died of acute respiratory distress syndrome (ARDS) 18 days
following injury. A second patient, a 52-year-old womanwith
a thoracic SCI, died of a cerebral malignant astrocytoma 11
months after injury. Subtle evidence of cerebral lesion was
seen on the admission brain CT on retrospective review al-
though it was not appreciated at the time of study entry.
Thoracic patients were included in the study primarily to
assess the safety of Cethrin. Thoracic patients were slow to
recruit because many patients with thoracic SCI often have
injuries that encompass a wide range of tissues and therefore
did not meet the inclusion/exclusion requirements. Thoracic
injuries are often associated with significantly more trauma to
surrounding tissues than are cervical injuries, creating an
environment that is more likely to allow for systemic ab-
sorption of the locally-administered Cethrin and potentially
greater systemic toxicity. Indeed, in the Phase I/IIa trial,
thoracic patients had approximately twice the blood levels of
Cethrin at a given dose than did cervical patients, except at the
9-mg dose.
The pharmacokinetic analysis, a secondary outcome mea-
sure, indicated that there was little systemic exposure to the
drug in patients. The mean Cmax value at the dose range of 1–
3mg for the cervical and thoracic patients was 0.8-2.3 ng/mL,
respectively, and was below the mean Cmax value for the ‘‘no
observed adverse effect’’ level determined from an extradural
toxicity study in rats. Moreover, the Cmax and AUC values for
the all of the patients in this study were below the Cmax and
AUC values for the low doses tested in the intravenous tox-
icity studies in rats and dogs. At all doses except the 9-mg
dose, the plasma levels were higher in the thoracic SCI pa-
tients than in the cervical patients. This discrepancy is prob-
ably because the thoracic spine is a much more stable
structure than the cervical spine, and a much more significant
trauma is required for a severe (ASIA A) injury of the thoracic
spinal cord. The greater traumatic disruption of the tissues in
the thoracic SCI patients increases the chance of systemic ex-
posure to an epidural injection. Variation in patient weight
could also contribute to variable systemic exposure.
It is reported that > 50% of people living with SCI have
some episodes of chronic neuropathic pain. Causing pain as
part of a treatment to promote regeneration of injured fibers is
a concern because some experimental treatments tested in
animals have been shown to stimulate fiber growth in central
pain pathways. However, pre-clinical studies in rats indicated
that the inactivation of Rho signalling would have no effect
on, or would even decrease, pain (Lord-Fontaine et al., 2008;
Ramer et al., 2004). In this clinical study painwas reported as a
treatment-emergent adverse event; therewas no evidence that
Cethrin affected pain, either positively or negatively.
Although this Phase I/IIa trial was open label and the
analysis was not blinded, the neurological outcomes are en-
couraging based on both ASIA motor scales in patients with
cervical injury, and the conversion rate from ASIA A to ASIA
C or D. We observed conversions to ASIA C or D in 31% of
patients with cervical SCI and in 6% of thoracic SCI patients.
When pooled, the conversion rates are typically higher in
cervical patients, and the predicted rate of conversion in a
untreated cervical SCI population would be £ 10% (Fawcett
et al., 2007). The observed change in cervical, but not thoracic,
patients is expected based on the anatomy of the spinal cord,
motor innervation patterns, and their relative contribution of
these differences to ASIA scoring (Fawcett et al., 2007).
FIG. 4. Change in motor score for cervical patients at 6 and
12 months. The average change in motor score – standard
deviation for the cervical patients is shown at 6 and 12
months.
FIG. 5. Conversion of cervical patients. Percent of patients
that converted from ASIA A to ASIA C (light grey) or to
ASIA D (dark grey) is shown for all of the dose groups.
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Whereas much emphasis is typically placed on motor recov-
ery, the fact that the cervical patients achieved substantial
sensory recovery is also noteworthy, as such sensation may
have a crucial protective function for skin areas that are sen-
sitive to pressure sores, and the sensory feedback may help in
seating balance (Anderson, 2004).
There is less spontaneous recovery in ASIA A patients than
in patients with incomplete injury, and based on a number of
published studies, recovery in ASIA A patients is quite pre-
dictable. In the first year after SCI, an ASIA A patient is ex-
pected to improve *10 ASIA motor points (Steeves et al.,
2007). Although we did not have a placebo arm in this safety
trial, the improvement in the cervical patients of 21.3 and 27.3
in the 1-mg and 3-mg dose groups, respectively, is very en-
couraging. However, it should be noted that many patients
living with SCI show some recovery after the first few days
under intensive care, and it has been argued that an ASIA
assessment at 24 h is not as reliable as one taken at 72 h when
the patient is more stable (Steeves et al., 2007). The continued
improvement that we observed between week 6 and week 52
(Fig. 3) is also encouraging. If some recovery were caused by
regeneration of injured fibers, this would be expected to be a
slow process, similar to what was observed.
At present, limited treatment options are available to pa-
tients with SCI, and the findings reported here on the safety
and tolerability of Cethrin indicate a potential new drug for
further study to treat acute SCI. Targeting Rho to foster both
neuroprotection and axon regeneration is well understood in
terms of mechanism of action, and a wealth of data from an-
imal studies provides good rationale for a progression to
clinical studies. We show here encouraging findings with a
small number of patients that indicate some evidence of effi-
cacy to enhance functional recovery. Further placebo-con-
trolled clinical trials in SCI with Cethrin will further our
understanding of the effects of this intervention on neuro-
logical recovery patterns and functional improvement in daily
activities.We hope that the success of this Phase I/IIa trial will
provide encouragement for the translation of other promising
therapies to treat SCI.
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